GLP-1 Medications and Cocaine: What the Rat Studies Show (and Why Human Trials Are Coming)

Cocaine use disorder has no FDA-approved pharmacotherapy. None. Despite decades of research, there is no medication a doctor can prescribe specifically to treat cocaine addiction. The same is true for methamphetamine. For the estimated 1.4 million Americans with cocaine use disorder and 1.6 million with methamphetamine use disorder, the treatment toolkit is limited to behavioral interventions.

That's what makes the emerging GLP-1 preclinical research so significant — not because it's ready for the clinic, but because it's targeting a pharmacological void.

The Animal Data

In September 2025, a study published in European Neuropsychopharmacology by Professor Elisabet Jerlhag's team demonstrated that semaglutide markedly reduced cocaine-seeking behavior in rat models. The researchers used established paradigms for measuring drug self-administration and relapse — gold-standard tests in addiction neuroscience.

This wasn't the first such finding. Earlier preclinical studies had shown that exendin-4 (an older GLP-1 receptor agonist) reduced cocaine-induced dopamine elevation in the nucleus accumbens and attenuated cocaine-conditioned place preference in mice. But the Jerlhag study was notable for using semaglutide specifically — the same molecule millions of people take as Ozempic and Wegovy — and for the consistency of the effect across multiple experimental paradigms.

The NTS → VTA Circuit

A 2025 study published in Molecular Neuroscience by Merkel et al. mapped the specific neural circuit involved. Using genetic tools, calcium imaging, and transcriptomic profiling, they identified a GABAergic pathway from the nucleus tractus solitarius (NTS) to the ventral tegmental area (VTA) that mediates the behavioral effects of GLP-1 receptor activation in cocaine models.

Amphetamines and Methamphetamine

The preclinical evidence extends beyond cocaine to other stimulants. Two studies using d-amphetamine showed that exendin-4 attenuated amphetamine-conditioned place preference in mice — meaning the animals found amphetamine less rewarding after GLP-1 receptor activation. And this isn't staying in the lab.

Why Stimulants Are Different

It's worth noting why the stimulant research is so far behind the alcohol and nicotine data. Several factors are at play:

No existing medication benchmark. For alcohol, researchers can compare GLP-1 medications against naltrexone, acamprosate, and disulfiram. For nicotine, against varenicline and bupropion. For cocaine and meth, there's nothing to compare against — which makes trial design more complex and regulatory pathways less established.

Patient recruitment challenges. Clinical trials for stimulant use disorders have historically high dropout rates. People with active cocaine or methamphetamine addiction are harder to enroll, retain, and follow up than people with alcohol use disorder. This makes trials more expensive and slower.

Different pharmacology. Cocaine and methamphetamine act through different mechanisms than alcohol or nicotine. Cocaine blocks dopamine reuptake; methamphetamine reverses the dopamine transporter and floods the synapse. Whether GLP-1's modulation of the reward pathway is strong enough to counteract these more direct dopaminergic effects is an open question that the preclinical data supports but hasn't definitively answered.

A Systematic Review's Verdict

A PRISMA-compliant systematic review published in Frontiers in Pharmacology in February 2026 synthesized 41 studies on GLP-1 receptor agonists and substance use disorders — 35 preclinical and 6 clinical. The authors concluded that preclinical evidence consistently demonstrates GLP-1 receptor agonists reduce substance-seeking behaviors across alcohol, nicotine, cocaine, and opioid models, with the proposed mechanism being modulation of mesolimbic dopaminergic signaling.

For stimulants specifically, they noted that the evidence is strong enough to justify human trials but cautioned that translation from rodent models to clinical practice requires several additional steps that haven't been taken yet.

The stimulant frontier is the furthest from clinical reality in the GLP-1 addiction story. But it may also be the most impactful if the research pans out — because it would fill a pharmacological gap that has persisted for the entire history of modern addiction medicine.